Colcrys is an anti-gout drug owned by Takeda Pharms Usa. The active ingredient in Colcrys is colchicine. It was first authorized for market use on 29 July, 2009 and is available in a tablet form for oral administration.
The generic version of Colcrys could potentially be released after 17th February, 2029. This is based on the expiry of its last patent, US8440721, titled 'Methods for concomitant administration of colchicine and a second active agent', which is set to expire on 17th February, 2029.
Colcrys is used in various methods for the prevention and treatment of gout flares. It's also used in the treatment of familial mediterranean fever. The effectiveness of Colcrys is attributed to its active ingredient, colchicines, which helps in preventing gout flares.
Colcrys holds a total of 17 drug patents, all of which are active. The last of these patents, US8440721, is set to expire on 17th February, 2029. The patents cover different compositions and methods of Colchicine, its uses, and concomitant administration with a second active agent. Below are the details of the patent: